Alexandria Real Estate Equities, Inc. (ARE)

Same-property NOI growth has decelerated to low-single-digits from high-single-digits during the 2021-2023 peak. This trails industrial REITs (Prologis) and data center REITs (Equinix, DLR) that benefit from stronger demand fundamentals. The development pipeline will add revenue but at lower initial yields than historically achieved.

ARE remains the undisputed leader in life science real estate with ~40M SF of operating and development properties. No competitor has a comparable portfolio in top-tier biotech clusters. However, new entrants (BioMed Realty/Blackstone, Healthpeak, IQHQ) have added significant competitive supply, diluting ARE's historically dominant market position.

Rental rate growth has stalled and is turning negative in some submarkets as sublease availability has tripled since 2022. ARE is offering increased tenant improvement allowances and free rent periods to maintain occupancy — a sharp reversal from the 2021 peak when tenants competed for space. Pricing power will remain weak until excess supply is absorbed.

ARE continues to develop state-of-the-art lab and office campuses, but delivering new supply into a softening market raises the risk of lower-than-projected returns on development capital. The firm has slowed new construction starts, which is prudent, but the existing pipeline will continue delivering for 2-3 more years regardless of market conditions.

Life science tenants face meaningful switching costs — lab buildouts cost $200-400/SF, and relocating specialized equipment and research operations is enormously disruptive. Proximity to talent, research institutions, and collaboration networks makes location choice strategic. However, sublease availability gives tenants more options without incurring relocation costs.

ARE's cluster strategy creates a genuine agglomeration effect — biotech companies want to be near other biotech companies, venture capital, research hospitals, and talent. ARE's campuses become innovation ecosystems that are more valuable in aggregate than the sum of individual buildings. This is a real but slow-moving competitive advantage.

Zoning restrictions in Cambridge, South San Francisco, and other top clusters limit new supply, protecting existing property values. However, municipalities have been increasingly approving life science zoning conversions in response to developer demand, and the supply wave of 2022-2025 demonstrates that regulatory barriers are not as impenetrable as previously believed.

Life science real estate is capital-intensive by definition — lab development costs $600-1000/SF, far more than conventional office. This deters casual entrants but also means ARE must continuously invest to maintain properties. Rising interest rates have increased the cost of capital, compressing development spreads and reducing the attractiveness of new projects.

FFO estimates have been revised downward over the past year as occupancy declines and concessions increase faster than expected. Analysts are modeling another 12-18 months of deteriorating fundamentals before a potential trough. The negative revision cycle has not yet stabilized.

The life science real estate oversupply narrative has become entrenched, with negative articles about rising vacancy and sublease availability dominating coverage. The broader REIT sector is out of favor due to interest rate sensitivity. GLP-1 drug success has paradoxically hurt biotech sentiment by drawing capital away from other therapeutic areas.

Founder CEO Joel Marcus stepped back from day-to-day operations, and the leadership transition adds uncertainty. The decision to aggressively develop during the 2021-2022 peak looks poorly timed in retrospect. ARE's balance sheet leverage has increased, and the company may need to slow development further or consider asset sales to maintain investment-grade credit metrics.